33 million people across desert coast, Andean highlands, and Amazon basin ; the Americas' highest tuberculosis burden, UPCH's globally connected tropical medicine legacy, a uniquely Peruvian Bartonellosis disease niche, Pacific Alliance network access, and Latin America's most competitive per-patient trial costs.
Peru's research proposition is built on infectious disease depth, geographic diversity, and cost leadership: the Americas' most concentrated TB and drug-resistant TB research platform through UPCH's globally connected IMTAvH infrastructure; three biologically distinct patient populations (coastal, Andean, Amazonian) within a single regulatory framework creating unmatched geographic diversity; a uniquely Peruvian disease niche in Bartonellosis that has no equivalent research platform elsewhere; and per-patient costs among Latin America's most competitive ; completing the Pacific Alliance research quartet of Chile, Colombia, and Mexico with a geography and disease burden that none of the others replicate.
DIGEMID regulatory authority under MINSA, with Good Clinical Practice framework under Resolution 021-2016-DG-DIGEMID incorporating ICH GCP E6(R2) principles; INS national coordination and REPEC clinical trial registry; institutional CEI ethics committees aligned with the Declaration of Helsinki; Pacific Alliance pharmaceutical harmonisation actively aligning Peruvian regulatory standards with Chile, Colombia, and Mexico; OECD accession process providing external accountability for regulatory standards development; NIH-CONCYTEC bilateral agreements supporting public-private clinical research collaboration frameworks.
Among Latin America's lowest per-patient and operational trial costs ; significantly below Chile, Colombia, Argentina, Brazil, and Mexico; PEN-denominated operational expenses highly competitive for USD and EUR-budgeted programs; Lima's cost structure substantially below Santiago or BogotĆ” for equivalent CRO and monitoring services; ESSALUD and SIS coverage creating structured patient access across both social security and public insurance pathways; Pacific Alliance regional programme coordination minimises per-country overhead when Peru anchors Colombia-Chile-Mexico multi-country designs as the cost-competitive southern Pacific node.
33M across three biomes ; coast, Andes, and Amazon ; with distinct genetic, epidemiological, and altitude-physiology profiles within one regulatory submission; Americas' highest TB burden (~30,000ā40,000 new cases/year) with disproportionate MDR-TB and XDR-TB; very high H. pylori prevalence (>80% in Andean communities) driving large gastric cancer patient pools; uniquely Peruvian Bartonella bacilliformis populations in inter-Andean valleys; Quechua and Aymara highland populations for altitude pharmacogenomics; malaria (vivax dominant) and leishmaniasis in Amazon; Afro-Peruvian and Asian-Peruvian ancestry subpopulations in Lima for pharmacogenomic diversity studies.
UPCH and its Hospital Nacional Cayetano Heredia ; Latin America's most internationally connected tropical medicine academic institution; IMTAvH (Instituto de Medicina Tropical "Alexander von Humboldt") with NIH, Johns Hopkins, and LSHTM partnerships; INEN (Instituto Nacional de Enfermedades NeoplĆ”sicas) coordinating national oncology research; Hospital Nacional Edgardo Rebagliati Martins (ESSALUD's flagship); Hospital Nacional Arzobispo Loayza and Hospital Dos de Mayo as major MINSA research anchors; ClĆnica Anglo Americana as Lima's established private research site; growing Lima CRO capacity (IQVIA, ICON, Syneos); regional sites in Arequipa, Cusco, and Iquitos for geographic and altitude-specific patient access.
Lima dominates Peruvian clinical research ; accounting for over 80% of national trial activity ; through the Hospital Nacional Cayetano Heredia/UPCH cluster, INEN, the ESSALUD flagship hospitals, and Lima's established private research sector. The geographic breadth of Peru's research is extended by regional sites in Arequipa (Peru's second city and gateway to the southern Andes), Cusco (the gateway to the high-altitude Andean plateau and the Quechua heartland), and Iquitos (the Amazon basin's largest city and the base for Peru's malaria, leishmaniasis, and tropical disease research programmes).
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Hospital Nacional Cayetano Heredia / UPCH ; IMTAvH | Lima | Peru's most internationally connected academic research hospital ; the clinical anchor of Universidad Peruana Cayetano Heredia (UPCH), Latin America's most globally networked tropical medicine research university ; operating in conjunction with the Instituto de Medicina Tropical "Alexander von Humboldt" (IMTAvH): the Americas' reference centre for TB, MDR-TB, malaria, leishmaniasis, dengue, and leptospirosis clinical research, with active NIH, CDC, Johns Hopkins Bloomberg School of Public Health, and London School of Hygiene and Tropical Medicine partnerships; Phase IāIV across infectious disease, TB (including the endTB and other landmark MDR-TB trials), malaria treatment, leishmaniasis chemotherapy, HIV, gastroenterology, and internal medicine; the single most important clinical research institution in Peru and the primary portal through which multinational infectious disease Phase IIāIII programmes activate Peruvian sites. |
| 02 | INEN ; Instituto Nacional de Enfermedades NeoplĆ”sicas | Lima | Peru's national cancer institute and the country's reference oncology treatment and research centre ; affiliated with the Ministerio de Salud and coordinating the national oncology trial network across Peru's MINSA hospital system; Phase IIāIV across solid tumours (gastric cancer, cervical cancer, colorectal cancer, breast cancer, and lung cancer ; all of significant national burden given Peru's H. pylori prevalence, HPV exposure rates, and rapidly growing cancer NCD burden) and haematological malignancies; INEN's investigator community has been central to Peru's growing commercial oncology Phase IIāIII portfolio and maintains established connections with international cooperative oncology groups; the national oncology registry administered through INEN provides the epidemiological data underlying commercial oncology trial feasibility assessments in Peru. |
| 03 | Hospital Nacional Edgardo Rebagliati Martins (ESSALUD) | Lima | Peru's largest hospital ; ESSALUD's flagship and one of the largest hospitals in South America ; covering formal sector workers and their dependants across Lima's largest managed care catchment; Phase IIāIV across cardiovascular, oncology, metabolic disease, haematology, neurology, and internal medicine; Hospital Rebagliati's sheer patient volume ; managing tens of thousands of outpatient consultations per day ; creates research access to one of Latin America's largest single-hospital patient populations for Phase III enrollment in cardiovascular, metabolic, and oncology indications; a critical site for sponsors designing Peru Phase III programs that require rapid enrollment through ESSALUD's structured patient identification and insurance coverage pathways. |
| 04 | Hospital Nacional Arzobispo Loayza | Lima | One of Lima's oldest and most research-historically active major public hospitals ; affiliated with the Universidad Nacional Mayor de San Marcos (UNMSM) Faculty of Medicine and serving the MINSA public hospital network ; with Phase IIāIII research activity across internal medicine, oncology, infectious disease, gastroenterology, and haematology; Hospital Loayza's patient catchment from Lima's working-class central districts provides access to large treatment-naĆÆve pools of mestizo and migrant highland Peruvian patients whose disease profile ; including gastric cancer, TB, and metabolic disease ; reflects the full complexity of Peru's epidemiological transition from infectious to chronic disease burden; an important public-sector complement to the ESSALUD and private hospital networks for sponsors requiring broad Lima public patient access. |
| 05 | Hospital Nacional Dos de Mayo | Lima | One of the oldest continuously operating hospitals in the Americas ; founded in 1875 on the site of the Hospital de Santa Ana established in 1549 ; and a major MINSA public research hospital affiliated with the Universidad Nacional Mayor de San Marcos Faculty of Medicine; Phase IIāIII across infectious disease, internal medicine, oncology, and gastroenterology; Hospital Dos de Mayo's long clinical tradition and its position as a reference hospital for Lima's central and northern working-class districts provide research access to large mestizo and highland-migrant Peruvian patient populations; its infectious disease department has historical experience in TB, leishmaniasis, and tropical disease research that predates Peru's modern clinical trial infrastructure and provides an institutional research culture receptive to international infectious disease trial partnerships. |
| 06 | Hospital Nacional Guillermo Almenara Irigoyen (ESSALUD) | Lima | ESSALUD's second major Lima hospital and one of Peru's most important Phase IIāIII research sites for cardiology, haematology, oncology, and nephrology; serves ESSALUD-covered formal sector workers in eastern Lima's large industrial and manufacturing districts, providing access to a demographically distinct patient catchment from Hospital Rebagliati's more geographically central coverage zone; the Hospital Almenara's haematology and oncology departments have been particularly active in clinical trial programs, with established pharmaceutical company relationships and an investigator community experienced in managing multinational Phase IIāIII commercial protocols within the ESSALUD administrative framework; an important secondary ESSALUD site for sponsors seeking Lima Phase III patient volume beyond what Hospital Rebagliati alone can enrol. |
| 07 | ClĆnica Anglo Americana | Lima | Lima's most established and internationally oriented private research hospital ; founded in 1939 to serve Lima's British and North American expatriate community and evolved into a fully integrated private clinical institution ; with Phase IIāIV commercial trial activity across oncology, cardiovascular, metabolic disease, and internal medicine; ClĆnica Anglo Americana's research department maintains the longest-standing established pharmaceutical company relationships of any Lima private hospital and operates to GCP documentation standards that reflect its decades of international pharmaceutical company partnership management; its Miraflores district patient catchment provides access to Lima's professional and upper-middle-income population ; a demographically distinct and Spanish-dominant research population complementary to the predominantly mestizo and working-class populations accessible through the MINSA and ESSALUD public hospital networks. |
| 08 | Hospital MarĆa Auxiliadora | Lima | A major MINSA general hospital in Villa MarĆa del Triunfo in southern Lima ; one of Lima's most populous and predominantly working-class metropolitan districts, heavily settled by Andean highland migrants from Ayacucho, ApurĆmac, and other southern highland regions ; with Phase IIāIII research activity across infectious disease, gastroenterology, and internal medicine; Hospital MarĆa Auxiliadora's patient catchment from southern Lima's migrant highland communities creates unique research access to Quechua-ancestry urban patients whose disease burden ; particularly TB, H. pylori-driven gastric disease, and diabetes in a recently urbanised indigenous population ; reflects the epidemiological consequences of Peru's internal migration from the Andean highlands to Lima over the past 30 years; an important MINSA site for sponsors requiring research access to Lima's highland-migrant Quechua-ancestry population within the Lima metropolitan research framework. |
| 09 | Hospital Regional de Loreto "Dr. Julio CĆ©sar Demarini Caro" | Iquitos | The primary research hospital for Peru's Amazon basin ; located in Iquitos, the world's largest city accessible only by air or river (no road connection to the rest of Peru) with approximately 400,000 inhabitants ; and the base for Peru's malaria, leishmaniasis, leptospirosis, dengue, and other Amazonian tropical disease clinical research; UPCH and the Amazonian Tropical Research Center (ACTTROPMED) operate research programmes through Hospital Loreto; Phase IāIII activity in malaria treatment and chemoprevention (Plasmodium vivax dominant in the Peruvian Amazon, with P. falciparum present in border zones), cutaneous leishmaniasis, dengue, and emerging flavivirus research; access to Amazonian indigenous patient populations ; some of the world's most genetically isolated ; makes Iquitos an irreplaceable site for tropical medicine Phase IIāIII programs requiring patient volumes that Lima's lower-transmission urban environment cannot provide. |
| 10 | Hospital Regional Honorio Delgado Espinoza | Arequipa | Arequipa's major public reference hospital ; affiliated with the Universidad Nacional de San AgustĆn (UNSA) Faculty of Medicine ; and the primary research institution for Peru's second city (~1.1 million), situated at 2,335m in the southern Andean foothills at the gateway to the high-altitude plateau; Phase IIāIII across oncology, cardiovascular, gastroenterology, and internal medicine; Arequipa's geographic position as the commercial and transport hub for southern Peru creates a research catchment extending into the high-altitude populations of the Puno plateau (Aymara-speaking communities around Lake Titicaca) and the Cusco highlands, providing access to altitude-adapted patient populations alongside the predominantly mestizo and White Arequipa urban population; an important southern Peru anchor for sponsors designing national multi-site networks extending beyond Lima. |
| 11 | Hospital Nacional Carlos Alberto SeguĆn Escobedo (ESSALUD Arequipa) | Arequipa | ESSALUD's flagship hospital in southern Peru ; the second largest ESSALUD hospital outside Lima ; covering the formal sector worker population of Arequipa and adjacent regions with Phase IIāIII research activity across cardiovascular, metabolic disease, oncology, and internal medicine; Hospital SeguĆn Escobedo's ESSALUD managed care patient base provides access to Arequipa's formally employed population ; a predominantly mestizo and White middle-class demographic ; whose research participation and follow-up compliance patterns reflect the structured healthcare engagement characteristic of ESSALUD's insurance system; an important complement to Hospital Honorio Delgado's MINSA public patient catchment for sponsors designing complete Arequipa Phase III site coverage across both healthcare systems. |
| 12 | Hospital Regional Cusco | Cusco | The primary reference hospital for the Cusco Region ; located in the historic Inca capital at 3,400m above sea level, serving a predominantly Quechua-speaking highland population of approximately 1.4 million ; and Peru's most important site for altitude medicine, high-altitude cardiovascular physiology, and chronic mountain sickness (Monge's disease) clinical research; Phase IIāIII across internal medicine, cardiovascular disease (particularly altitude-related right heart disease and pulmonary hypertension), gastroenterology (H. pylori and gastric cancer in a high-prevalence highland population), and infectious disease; Hospital Regional Cusco's altitude and Quechua-ancestry patient population make it the only major research hospital in Peru positioned to enrol patients with the physiological adaptations and altitude-specific disease burden of permanent Andean highlanders ; an irreplaceable site for sponsors whose programs require pharmacokinetic or pharmacodynamic data in high-altitude populations, or who need enrollment in altitude-adapted cardiovascular and pulmonary disease patient cohorts. |
Peru's most internationally connected academic research hospital ; the clinical anchor of Universidad Peruana Cayetano Heredia (UPCH), Latin America's most globally networked tropical medicine research university ; operating in conjunction with the Instituto de Medicina Tropical "Alexander von Humboldt" (IMTAvH): the Americas' reference centre for TB, MDR-TB, malaria, leishmaniasis, dengue, and leptospirosis clinical research, with active NIH, CDC, Johns Hopkins Bloomberg School of Public Health, and London School of Hygiene and Tropical Medicine partnerships; Phase IāIV across infectious disease, TB (including the endTB and other landmark MDR-TB trials), malaria treatment, leishmaniasis chemotherapy, HIV, gastroenterology, and internal medicine; the single most important clinical research institution in Peru and the primary portal through which multinational infectious disease Phase IIāIII programmes activate Peruvian sites.
Peru's national cancer institute and the country's reference oncology treatment and research centre ; affiliated with the Ministerio de Salud and coordinating the national oncology trial network across Peru's MINSA hospital system; Phase IIāIV across solid tumours (gastric cancer, cervical cancer, colorectal cancer, breast cancer, and lung cancer ; all of significant national burden given Peru's H. pylori prevalence, HPV exposure rates, and rapidly growing cancer NCD burden) and haematological malignancies; INEN's investigator community has been central to Peru's growing commercial oncology Phase IIāIII portfolio and maintains established connections with international cooperative oncology groups; the national oncology registry administered through INEN provides the epidemiological data underlying commercial oncology trial feasibility assessments in Peru.
Peru's largest hospital ; ESSALUD's flagship and one of the largest hospitals in South America ; covering formal sector workers and their dependants across Lima's largest managed care catchment; Phase IIāIV across cardiovascular, oncology, metabolic disease, haematology, neurology, and internal medicine; Hospital Rebagliati's sheer patient volume ; managing tens of thousands of outpatient consultations per day ; creates research access to one of Latin America's largest single-hospital patient populations for Phase III enrollment in cardiovascular, metabolic, and oncology indications; a critical site for sponsors designing Peru Phase III programs that require rapid enrollment through ESSALUD's structured patient identification and insurance coverage pathways.
One of Lima's oldest and most research-historically active major public hospitals ; affiliated with the Universidad Nacional Mayor de San Marcos (UNMSM) Faculty of Medicine and serving the MINSA public hospital network ; with Phase IIāIII research activity across internal medicine, oncology, infectious disease, gastroenterology, and haematology; Hospital Loayza's patient catchment from Lima's working-class central districts provides access to large treatment-naĆÆve pools of mestizo and migrant highland Peruvian patients whose disease profile ; including gastric cancer, TB, and metabolic disease ; reflects the full complexity of Peru's epidemiological transition from infectious to chronic disease burden; an important public-sector complement to the ESSALUD and private hospital networks for sponsors requiring broad Lima public patient access.
One of the oldest continuously operating hospitals in the Americas ; founded in 1875 on the site of the Hospital de Santa Ana established in 1549 ; and a major MINSA public research hospital affiliated with the Universidad Nacional Mayor de San Marcos Faculty of Medicine; Phase IIāIII across infectious disease, internal medicine, oncology, and gastroenterology; Hospital Dos de Mayo's long clinical tradition and its position as a reference hospital for Lima's central and northern working-class districts provide research access to large mestizo and highland-migrant Peruvian patient populations; its infectious disease department has historical experience in TB, leishmaniasis, and tropical disease research that predates Peru's modern clinical trial infrastructure and provides an institutional research culture receptive to international infectious disease trial partnerships.
ESSALUD's second major Lima hospital and one of Peru's most important Phase IIāIII research sites for cardiology, haematology, oncology, and nephrology; serves ESSALUD-covered formal sector workers in eastern Lima's large industrial and manufacturing districts, providing access to a demographically distinct patient catchment from Hospital Rebagliati's more geographically central coverage zone; the Hospital Almenara's haematology and oncology departments have been particularly active in clinical trial programs, with established pharmaceutical company relationships and an investigator community experienced in managing multinational Phase IIāIII commercial protocols within the ESSALUD administrative framework; an important secondary ESSALUD site for sponsors seeking Lima Phase III patient volume beyond what Hospital Rebagliati alone can enrol.
Lima's most established and internationally oriented private research hospital ; founded in 1939 to serve Lima's British and North American expatriate community and evolved into a fully integrated private clinical institution ; with Phase IIāIV commercial trial activity across oncology, cardiovascular, metabolic disease, and internal medicine; ClĆnica Anglo Americana's research department maintains the longest-standing established pharmaceutical company relationships of any Lima private hospital and operates to GCP documentation standards that reflect its decades of international pharmaceutical company partnership management; its Miraflores district patient catchment provides access to Lima's professional and upper-middle-income population ; a demographically distinct and Spanish-dominant research population complementary to the predominantly mestizo and working-class populations accessible through the MINSA and ESSALUD public hospital networks.
A major MINSA general hospital in Villa MarĆa del Triunfo in southern Lima ; one of Lima's most populous and predominantly working-class metropolitan districts, heavily settled by Andean highland migrants from Ayacucho, ApurĆmac, and other southern highland regions ; with Phase IIāIII research activity across infectious disease, gastroenterology, and internal medicine; Hospital MarĆa Auxiliadora's patient catchment from southern Lima's migrant highland communities creates unique research access to Quechua-ancestry urban patients whose disease burden ; particularly TB, H. pylori-driven gastric disease, and diabetes in a recently urbanised indigenous population ; reflects the epidemiological consequences of Peru's internal migration from the Andean highlands to Lima over the past 30 years; an important MINSA site for sponsors requiring research access to Lima's highland-migrant Quechua-ancestry population within the Lima metropolitan research framework.
The primary research hospital for Peru's Amazon basin ; located in Iquitos, the world's largest city accessible only by air or river (no road connection to the rest of Peru) with approximately 400,000 inhabitants ; and the base for Peru's malaria, leishmaniasis, leptospirosis, dengue, and other Amazonian tropical disease clinical research; UPCH and the Amazonian Tropical Research Center (ACTTROPMED) operate research programmes through Hospital Loreto; Phase IāIII activity in malaria treatment and chemoprevention (Plasmodium vivax dominant in the Peruvian Amazon, with P. falciparum present in border zones), cutaneous leishmaniasis, dengue, and emerging flavivirus research; access to Amazonian indigenous patient populations ; some of the world's most genetically isolated ; makes Iquitos an irreplaceable site for tropical medicine Phase IIāIII programs requiring patient volumes that Lima's lower-transmission urban environment cannot provide.
Arequipa's major public reference hospital ; affiliated with the Universidad Nacional de San AgustĆn (UNSA) Faculty of Medicine ; and the primary research institution for Peru's second city (~1.1 million), situated at 2,335m in the southern Andean foothills at the gateway to the high-altitude plateau; Phase IIāIII across oncology, cardiovascular, gastroenterology, and internal medicine; Arequipa's geographic position as the commercial and transport hub for southern Peru creates a research catchment extending into the high-altitude populations of the Puno plateau (Aymara-speaking communities around Lake Titicaca) and the Cusco highlands, providing access to altitude-adapted patient populations alongside the predominantly mestizo and White Arequipa urban population; an important southern Peru anchor for sponsors designing national multi-site networks extending beyond Lima.
ESSALUD's flagship hospital in southern Peru ; the second largest ESSALUD hospital outside Lima ; covering the formal sector worker population of Arequipa and adjacent regions with Phase IIāIII research activity across cardiovascular, metabolic disease, oncology, and internal medicine; Hospital SeguĆn Escobedo's ESSALUD managed care patient base provides access to Arequipa's formally employed population ; a predominantly mestizo and White middle-class demographic ; whose research participation and follow-up compliance patterns reflect the structured healthcare engagement characteristic of ESSALUD's insurance system; an important complement to Hospital Honorio Delgado's MINSA public patient catchment for sponsors designing complete Arequipa Phase III site coverage across both healthcare systems.
The primary reference hospital for the Cusco Region ; located in the historic Inca capital at 3,400m above sea level, serving a predominantly Quechua-speaking highland population of approximately 1.4 million ; and Peru's most important site for altitude medicine, high-altitude cardiovascular physiology, and chronic mountain sickness (Monge's disease) clinical research; Phase IIāIII across internal medicine, cardiovascular disease (particularly altitude-related right heart disease and pulmonary hypertension), gastroenterology (H. pylori and gastric cancer in a high-prevalence highland population), and infectious disease; Hospital Regional Cusco's altitude and Quechua-ancestry patient population make it the only major research hospital in Peru positioned to enrol patients with the physiological adaptations and altitude-specific disease burden of permanent Andean highlanders ; an irreplaceable site for sponsors whose programs require pharmacokinetic or pharmacodynamic data in high-altitude populations, or who need enrollment in altitude-adapted cardiovascular and pulmonary disease patient cohorts.
These are the primary regulatory, academic, and industry bodies shaping Peru's clinical research ecosystem.
DIGEMID ; DirecciĆ³n General de Medicamentos, Insumos y Drogas
INS ; Instituto Nacional de Salud / REPEC
CONCYTEC ; Consejo Nacional de Ciencia, TecnologĆa e InnovaciĆ³n TecnolĆ³gica
UPCH ; Universidad Peruana Cayetano Heredia
IMTAvH ; Instituto de Medicina Tropical "Alexander von Humboldt" (UPCH)
UNMSM ; Universidad Nacional Mayor de San Marcos, Facultad de Medicina "San Fernando"
INEN ; Instituto Nacional de Enfermedades NeoplƔsicas
IQVIA Peru
ICON plc (Peru)
Syneos Health (Peru)
Farmaindustria ; AsociaciĆ³n Nacional de Laboratorios FarmacĆ©uticos del PerĆŗ
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.